Lilly to buy three infectious disease companies for up to about $3.8 billion

Eli Lilly announced on May 26, 2026 that it has agreements to acquire three companies — Curevo, LimmaTech Biologics and Vaccine Company — in deals worth up to about $3.8 billion in cash, expanding its research and development into infectious disease ^[1]. Lilly described the moves as building on its existing infectious disease work ^[1].

Each deal pays an upfront amount plus later payments tied to milestones, so the maximum totals are reached only if the programs meet specific goals. Lilly put the Curevo deal at up to $1.5 billion, LimmaTech Biologics at up to $780 million, and Vaccine Company at up to $1.55 billion ^[1].

Curevo's lead candidate is amezosvatein, an adjuvanted subunit vaccine intended to prevent shingles in adults ^[1]. Lilly said the current standard of care works, but that tolerability problems can hold down vaccination rates and lead to missed second doses, leaving some patients with reduced or no protection ^[1]. In a Phase 2 trial comparing the two head-to-head, amezosvatein matched the standard of care on immune response across all primary endpoints and cut side effects such as activity-limiting fatigue, chills and pain at the injection site by more than half, according to the company ^[1]. Lilly also said growing evidence links shingles to elevated stroke risk, and that shingles vaccination is associated with reduced dementia risk ^[1]. The announcement does not say whether the Phase 2 results have been published in a peer-reviewed journal.

LimmaTech Biologics is developing vaccines against bacterial pathogens for which antibiotic resistance is narrowing treatment options, including Staphylococcus aureus, Neisseria gonorrhoeae and Chlamydia trachomatis ^[1]. Its lead program, LTB-SA7, is in Phase 1 testing against S. aureus, which Lilly calls the leading cause of surgical-site infection; the platform targets the toxins and superantigens that drive disease ^[1]. Earlier-stage programs target pathogens that cause infertility and other long-term consequences that Lilly says fall disproportionately on women ^[1].

Vaccine Company's lead program uses an In Vivo Nanoparticle platform to display antigens in a way meant to produce durable immune responses, with a five-antigen candidate against Epstein-Barr virus that Lilly describes as Phase 1-ready ^[1]. Lilly cites evidence linking EBV to multiple sclerosis and several cancers, and says a preventive vaccine could head off not only infectious mononucleosis but later neurological and oncological effects ^[1].

"These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences," said Daniel M. Skovronsky, Lilly's chief scientific and product officer and president of Lilly Research Laboratories ^[1]. He pointed to evidence tying common infections to neurological disease, cancer and infertility that can emerge years later, and said that as antibiotic resistance erodes treatment options, vaccines are "increasingly the only path to prevention" ^[1].

Why it matters for patients

None of this changes the GLP-1 medicines people are already taking. All three companies' product candidates are investigational and have not been approved by any regulatory authority ^[1]. The announcement does not cover tirzepatide (Mounjaro, Zepbound) or semaglutide (Ozempic, Wegovy, Rybelsus), and no changes to availability, labeling, pricing or insurance coverage of those products were announced ^[1].

What the deals do show is where Lilly is spending beyond the obesity and diabetes business that has driven its recent growth. Lilly's incretin franchise has been described as funding the company's next areas of research ^[2]. The money committed here — up to $3.8 billion, contingent on milestones — signals that vaccines are one of those areas ^[1].

For older adults, the shingles program is the most concrete item. A better-tolerated shingles vaccine could matter for people who skip or delay the second dose because of side effects, but the evidence so far is a company-reported Phase 2 comparison, not an approval ^[1]. No information was disclosed about what these vaccines would cost or whether insurers would cover them ^[1].

What happens next

The transactions are subject to customary closing conditions, including expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ^[1]. Lilly said it will determine the accounting treatment after closing, and that the deals will then show up in its financial results and guidance ^[1]. No expected closing date was disclosed, and the announcement gives no timelines for further trial results ^[1]. Later milestone payments depend on clinical, regulatory and commercial goals that Lilly did not detail beyond the maximum totals ^[1].